-       Report 
- May 2024
-  140 Pages 
- Global 
   From       €4941EUR$5,524USD£4,346GBP 
      €5813EUR$6,499USD£5,113GBP 
          -       Report 
- May 2023
-  130 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
            -       Report 
- July 2024
-  100 Pages 
- Global 
   From       €2683EUR$3,000USD£2,360GBP 
      €3354EUR$3,750USD£2,950GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
           -       Report 
- August 2022
-  116 Pages 
- Global 
   From       €4249EUR$4,750USD£3,737GBP 
          -       Report 
- August 2024
-  150 Pages 
- Global 
   From       €2495EUR$2,789USD£2,194GBP 
          -       Report 
- July 2024
-  200 Pages 
- Global 
   From       €4427EUR$4,949USD£3,894GBP 
            -       Report 
- September 2024
-  150 Pages 
- Global 
   From       €3444EUR$3,850USD£3,029GBP 
      €4338EUR$4,850USD£3,816GBP 
             Uterine Fibroids Drug market is a segment of the Women's Health industry that focuses on the treatment of uterine fibroids. Uterine fibroids are non-cancerous growths that can cause heavy menstrual bleeding, pelvic pain, and other symptoms. Treatment options include medications, minimally invasive procedures, and surgery. Medications used to treat uterine fibroids include gonadotropin-releasing hormone agonists, progestins, androgens, and selective progesterone receptor modulators. Minimally    invasive procedures include uterine artery embolization, endometrial ablation, and myolysis. Surgery is the most invasive option and includes hysterectomy and myomectomy.
Companies in the Uterine Fibroids Drug market include AbbVie, Bayer, Pfizer, Allergan, and Merck. Show Less   Read more